文献速递新发突发、热带与寄生虫病

早期额外麻疹疫苗对死亡率和抗体水平的两中心随机试验

A Two-Center Randomized Trial of an Additional Early Dose of Measles Vaccine: Effects on Mortality and Measles Antibody Levels.
PubMed 文献 · Clin Infect Dis · 2018-01-01

在布基纳法索和几内亚比绍的4-7月龄儿童中,随机给予额外早期麻疹疫苗或不予额外接种,评估至3岁死亡率及麻疹抗体水平。结果显示额外早期麻疹疫苗未降低全因死亡率(HR 1.05,95%CI 0.75-1.46),但大多数儿童在4-7月龄时对麻疹易感,早期接种后抗体应答率高。

要点

  • 额外早期麻疹疫苗未降低4-7月龄至3岁儿童的全因死亡率。
  • 4-7月龄时多数儿童缺乏保护性麻疹抗体,早期接种后92%产生保护水平。
  • 至9月龄未接种麻疹疫苗且未暴露儿童无保护性抗体,早期接种者抗体应答良好。

核心结论

  • 额外早期麻疹疫苗未降低全因死亡率,但大多数4-7月龄儿童对麻疹易感,早期接种后抗体应答率高。

研究设计与样本

  • 两中心随机对照试验,在布基纳法索和几内亚比绍农村卫生与人口监测点纳入4-7月龄儿童,1:1随机接受额外早期标准剂量麻疹疫苗(Edmonston-Zagreb株)或不接种,所有儿童9月龄接受常规麻疹疫苗。
  • 共纳入8309名儿童,随机时间2012年7月18日至2015年12月3日,通过家访评估死亡率,随访至3岁。
  • 部分参与者采血评估麻疹抗体水平。

主要发现

  • 共登记145例死亡,死亡率为16/1000人年,死亡率低于预期且组间无差异(HR 1.05,95%CI 0.75-1.46)。
  • 入组时,布基纳法索4%(16/447)和几内亚比绍21%(90/422)的儿童有保护性麻疹抗体水平。
  • 至9月龄时,未接种麻疹疫苗且未暴露的儿童均无保护性抗体水平,而早期麻疹疫苗受种者中92%(306/333)有保护性水平。
  • 末次随访时,早期麻疹疫苗组98%(186/189)和对照组97%(196/202)有保护性抗体水平。

临床怎么用

  • 对于4-7月龄儿童,额外早期麻疹疫苗不能降低全因死亡率,但可提高麻疹抗体保护水平。
  • 在麻疹易感且死亡率低的地区,早期接种麻疹疫苗的死亡率获益不显著,但免疫原性良好。

局限性

  • 死亡率低于预期可能影响死亡结局的统计效能。
  • 抗体亚组分析样本量有限,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In addition to protecting against measles, measles vaccine (MV) may have beneficial nonspecific effects. We tested the effect of an additional early MV on mortality and measles antibody levels. METHODS: Children aged 4-7 months at rural health and demographic surveillance sites in Burkina Faso and Guinea-Bissau were randomized 1:1 to an extra early standard dose of MV (Edmonston-Zagreb strain) or no extra MV 4 weeks after the third diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine. All children received routine MV at 9 months. We assessed mortality through home visits and compared mortality from enrollment to age 3 years using Cox proportional hazards models, censoring for subsequent nontrial MV. Subgroups of participants had blood sampled to assess measles antibody levels. RESULTS: Among 8309 children enrolled from 18 July 2012 to 3 December 2015, we registered 145 deaths (mortality rate: 16/1000 person-years). The mortality was lower than anticipated and did not differ by randomization group (hazard ratio, 1.05; 95% confidence interval, 0.75-1.46). At enrollment, 4% (16/447) of children in Burkina Faso and 21% (90/422) in Guinea-Bissau had protective measles antibody levels. By age 9 months, no measles-unvaccinated/-unexposed child had protective levels, while 92% (306/333) of early MV recipients had protective levels. At final follow-up, 98% (186/189) in the early MV group and 97% (196/202) in the control group had protective levels. CONCLUSIONS: Early MV did not reduce all-cause mortality. Most children were susceptible to measles infection at age 4-7 months and responded with high antibody levels to early MV. CLINICAL TRIALS REGISTRATION: NCT01644721.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Fisker AB, Nebie E, Schoeps A, et al. A Two-Center Randomized Trial of an Additional Early Dose of Measles Vaccine: Effects on Mortality and Measles Antibody Levels. Clin Infect Dis. 2018. PMID: 29177407. doi:10.1093/cid/cix1033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。